Analysts suspected that the mid-stage trial miss wouldn't ding Neurocrine’s share price since expectations around the program were "near-zero." ...

The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a ...

The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.

Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in ...

Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.

The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...